{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T21:07:57Z","timestamp":1762376877248,"version":"build-2065373602"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.canlet.2021.01.027","type":"journal-article","created":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T22:15:18Z","timestamp":1612304118000},"page":"151-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Immunization with alloantibodies-covered melanoma cells induces regional antitumor effects that become systemic when combined with 5-FU treatment"],"prefix":"10.1016","volume":"503","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0264-2969","authenticated-orcid":false,"given":"Nana","family":"Dang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Waer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1314-9675","authenticated-orcid":false,"given":"Ben","family":"Sprangers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2021.01.027_bib1","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1111\/trf.15306","article-title":"Red blood cell alloantibodies are associated with increased alloimmunization against human leukocyte antigens","volume":"59","author":"Belizaire","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.canlet.2021.01.027_bib2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3389\/fimmu.2016.00030","article-title":"Following sensitization to human leukocyte antigen","volume":"7","author":"Hickey","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2021.01.027_bib3","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1111\/ajt.15813","article-title":"Novel therapeutic opportunities afforded by plasma cell biology in transplantation","volume":"20","author":"Agarwal","year":"2020","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.canlet.2021.01.027_bib4","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/ajt.15754","article-title":"Development and outcomes of de novo donor-specific antibodies in low, moderate, and high immunological risk kidney transplant recipients","volume":"20","author":"Wan","year":"2020","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.canlet.2021.01.027_bib5","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/ajt.12984","article-title":"B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) mediate CD40-independent help by memory CD4 T cells","volume":"15","author":"Gorbacheva","year":"2015","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.canlet.2021.01.027_bib6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature14424","article-title":"Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity","volume":"521","author":"Carmi","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2021.01.027_bib7","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.3390\/cancers11111694","article-title":"Improved anti-tumour adaptive immunity can overcome the melanoma immunosuppressive tumour microenvironment","volume":"11","author":"Dang","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2021.01.027_bib8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1172\/JCI0215640","article-title":"Immune complex\u2013mediated antigen presentation induces tumor immunity","volume":"110","author":"Rafiq","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2021.01.027_bib9","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.4049\/jimmunol.176.8.4573","article-title":"Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine","volume":"176","author":"Schuurhuis","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2021.01.027_bib10","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1158\/0008-5472.CAN-18-3143","article-title":"Solid tumor\u2013induced immune regulation alters the GvHD\/GvT paradigm after allogenic bone marrow transplantation","volume":"79","author":"Dang","year":"2019","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2021.01.027_bib11","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1158\/2326-6066.CIR-19-0666","article-title":"Donor lymphocyte-derived nature killer cells control MHC class I-negative melanoma","volume":"8","author":"Dang","year":"2020","journal-title":"Cancer Immunol Res."},{"key":"10.1016\/j.canlet.2021.01.027_bib12","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ijc.2910610420","article-title":"Expression of protectin (CD59) in human melanoma and its functional role in cell- and complement-mediated cytotoxicity","volume":"61","author":"Brasoveanu","year":"1995","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.canlet.2021.01.027_bib13","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/s41419-019-2065-4","article-title":"Pancreatic cancer-educated macrophages protect cancer cells from complement-dependent cytotoxicity by up-regulation of CD59","volume":"10","author":"Zhang","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2021.01.027_bib14","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ymthe.2017.11.009","article-title":"mRNA vaccine with antigen-specific checkpoint blockade induces an enhanced immune response against established melanoma","volume":"26","author":"Wang","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2021.01.027_bib15","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/eji.201545797","article-title":"The site of tumor development determines immunogenicity via temporal mobilization of antigen-laden dendritic cells in draining lymph nodes,","volume":"46","author":"Joncker","year":"2015","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.canlet.2021.01.027_bib16","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1342918","article-title":"Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer","volume":"6","author":"Malesci","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2021.01.027_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/science.aax0182","article-title":"Neoadjuvant checkpoint blockade for cancer immunotherapy","volume":"367","author":"Topalian","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.canlet.2021.01.027_bib18","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89020","article-title":"Akt and SHP-1 are DC-intrinsic checkpoints for tumor immunity","volume":"1","author":"Carmi","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.canlet.2021.01.027_bib19","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1158\/2159-8290.CD-18-0743","article-title":"Situ vaccination with a TLR9 agonist and local low-dose radiation induces systemic responses in untreated indolent lymphoma","volume":"8","author":"Frank","year":"2018","journal-title":"Canc. Discov."},{"key":"10.1016\/j.canlet.2021.01.027_bib20","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1158\/2326-6066.CIR-14-0024","article-title":"Therapeutic in situ autovaccination against solid cancers with intratumoral poly-ICLC: case report, hypothesis, and clinical trial","volume":"2","author":"Salazar","year":"2014","journal-title":"Cancer Immunol Res."},{"key":"10.1016\/j.canlet.2021.01.027_bib21","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1158\/2159-8290.CD-13-0458","article-title":"Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation","volume":"4","author":"Bald","year":"2014","journal-title":"Canc. Discov."},{"key":"10.1016\/j.canlet.2021.01.027_bib22","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2021.01.027_bib23","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2021.01.027_bib24","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.4049\/jimmunol.174.12.7516","article-title":"Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor","volume":"174","author":"Lugade","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2021.01.027_bib25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/hum.2005.16.35","article-title":"Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy","volume":"16","author":"Heinzerling","year":"2005","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.canlet.2021.01.027_bib26","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/sj.cgt.7701064","article-title":"Intratumoral injection of IL-12 plasmid DNA \u2013 results of a phase I\/IB clinical trial","volume":"14","author":"Mahvi","year":"2007","journal-title":"Canc. Gene Ther."},{"key":"10.1016\/j.canlet.2021.01.027_bib27","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1172\/JCI64859","article-title":"Depleting tumor-specific Tregs at a single site eradicates disseminated tumors","volume":"123","author":"Marabelle","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2021.01.027_bib28","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.molonc.2015.10.016","article-title":"In situ vaccination: cancer immunotherapy both personalized and off-the-shelf","volume":"9","author":"Hammerich","year":"2015","journal-title":"Mol Oncol"},{"key":"10.1016\/j.canlet.2021.01.027_bib29","article-title":"Complement dependent cytotoxicity activity of therapeutic antibody fragments is acquired by immunogenic glycan coupling","author":"Courtois","year":"2012","journal-title":"Electron. J. Biotechnol."},{"key":"10.1016\/j.canlet.2021.01.027_bib30","doi-asserted-by":"crossref","first-page":"6734","DOI":"10.1158\/0008-5472.CAN-08-0502","article-title":"Modulation of protective T cell immunity by complement inhibitor expression on tumor cells","volume":"68","author":"Varela","year":"2008","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2021.01.027_bib31","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1158\/0008-5472.CAN-10-2788","article-title":"Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis","volume":"71","author":"Schiavoni","year":"2011","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2021.01.027_bib32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0065-2776(06)90002-9","article-title":"Mechanisms of immune evasion by tumors","volume":"90","author":"Drake","year":"2006","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.canlet.2021.01.027_bib33","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrc1630","article-title":"Immunotherapy for pancreatic cancer \u2014 science driving clinical progress","volume":"5","author":"Laheru","year":"2005","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.canlet.2021.01.027_bib34","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1084\/jem.20030448","article-title":"Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming","volume":"198","author":"Mart\u00edn-Fontecha","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2021.01.027_bib35","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.coi.2013.11.002","article-title":"Organization of the mouse and human DC network","volume":"26","author":"Schlitzer","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.canlet.2021.01.027_bib36","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.1164206","article-title":"Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T Cell immunity","volume":"322","author":"Hildner","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.canlet.2021.01.027_bib37","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1158\/0008-5472.CAN-17-2426","article-title":"CD4+ T-cell\u2013mediated rejection of MHC class II\u2013positive tumor cells is dependent on antigen secretion and indirect presentation on host APCs","volume":"78","author":"Haabeth","year":"2018","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2021.01.027_bib38","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/30996","article-title":"Help for cytotoxic-T-cell responses is mediated by CD40 signalling","volume":"393","author":"Bennett","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2021.01.027_bib39","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/30989","article-title":"A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell,","volume":"393","author":"Ridge","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2021.01.027_bib40","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/31002","article-title":"T-cell help for cytotoxic T lymphocytes is mediated by CD40\u2013CD40L interactions","volume":"393","author":"Schoenberger","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2021.01.027_bib41","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ccell.2016.08.004","article-title":"T cell cancer therapy requires CD40-CD40L activation of tumor necrosis factor and inducible nitric-oxide-synthase-producing dendritic cells","volume":"30","author":"Marigo","year":"2016","journal-title":"Canc. Cell"},{"key":"10.1016\/j.canlet.2021.01.027_bib42","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1158\/1078-0432.CCR-06-1893","article-title":"Prospect of targeting the CD40 pathway for cancer therapy","volume":"13","author":"Vonderheide","year":"2007","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2021.01.027_bib43","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1084\/jem.20160062","article-title":"Absence of MHC class II on cDCs results in microbial-dependent intestinal inflammation","volume":"213","author":"Loschko","year":"2016","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2021.01.027_bib44","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1365-2567.2006.02464.x","article-title":"Dendritic cells, but not macrophages or B cells, activate major histocompatibility complex class II-restricted CD4+T cells upon immune-complex uptake in vivo","volume":"119","author":"de Jong","year":"2006","journal-title":"Immunology"},{"key":"10.1016\/j.canlet.2021.01.027_bib45","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrc3246","article-title":"The determinants of tumour immunogenicity,","volume":"12","author":"Blankenstein","year":"2012","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.canlet.2021.01.027_bib46","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fcell.2019.00050","article-title":"Immunogenic cell death and immunotherapy of multiple myeloma","volume":"7","author":"Serrano-del Valle","year":"2019","journal-title":"Front Cell Dev Biol."},{"key":"10.1016\/j.canlet.2021.01.027_bib47","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.cell.2016.12.022","article-title":"Systemic immunity is required for effective cancer immunotherapy","volume":"168","author":"Spitzer","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2021.01.027_bib48","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1158\/2326-6066.CIR-17-0353","article-title":"Tumor-specific inhibition of in situ vaccination by distant untreated tumor sites","volume":"6","author":"Morris","year":"2018","journal-title":"Cancer Immunol Res."},{"key":"10.1016\/j.canlet.2021.01.027_bib49","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1200\/JCO.2010.28.9793","article-title":"Situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I\/II study,","volume":"28","author":"Brody","year":"2010","journal-title":"J. Clin. Oncol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521000513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521000513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:55:00Z","timestamp":1759593300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383521000513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":49,"alternative-id":["S0304383521000513"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2021.01.027","relation":{},"ISSN":["0304-3835"],"issn-type":[{"type":"print","value":"0304-3835"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunization with alloantibodies-covered melanoma cells induces regional antitumor effects that become systemic when combined with 5-FU treatment","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2021.01.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}